The impact of pembrolizumab 200 mg (i.v. on day 14) has been assessed also in association with high-dose cytarabine in 37 R/R AML patients (9/37, 24%, bearing NPM1 mutations) [137]. The gene discussed is NPM1; the disease is acute myeloid leukemia.